VNDA stock forecast
Our latest prediction for Vanda Pharmaceuticals, Inc.'s stock price was made on the March 4, 2019 when the stock price was at 19.84$.
In the short term (2weeks), VNDA's stock price should outperform the market by 0.66%. During that period the price should oscillate between -7.41% and +9.50%.
In the medium term (3months), VNDA's stock price should outperform the market by 4.60%. During that period the price should oscillate between -16.66% and +24.87%.Get email alerts
About Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
At the moment the company generates 219M USD in revenues.
On its last earning announcement, the company reported a profit of 2.23$ per share.
The book value per share is 4.80$
Three months stock forecastMarch 4, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|